Xenon Pharmaceuticals, is this for real?

If you follow biotech at all, you probably caught the headline in early March. A Canadian company you may never have heard of just reported clinical trial results that sent analysts scrambling for superlatives. The Baird analyst covering the space had said a 32% placebo-adjusted effect would be a home run. Xenon Pharmaceuticals hit 43%. In a field where Phase 3 studies routinely disappoint, that kind of overshoot stops you in your tracks.

So in this edition, I want to take a closer look at Xenon and ask the question: is this for real?

Founded in Vancouver in 1996 and listed on Nasdaq in 2016, Xenon has spent decades quietly building expertise in ion channel biology, the science of how electrical signals travel through cells. For most of its history it was a preclinical shop, licensing early-stage assets and staying out of the spotlight. That changed when it decided to take its lead drug, azetukalner, all the way through clinical development itself. That bet is now looking like one of the better decisions in recent biotech history.

To understand why the data matter, you need to understand the problem azetukalner is trying to solve. Epilepsy affects roughly 50 million people worldwide, and focal onset seizures, the most common type, are experienced by about 1.8 million Americans. These are seizures that originate in a specific region of the brain before potentially spreading. The patients Xenon enrolled in its trials were not mild cases; they were averaging 13 seizures per month despite already being on multiple medications. About half of all epilepsy patients never achieve full seizure control on existing drugs, and the drugs that exist today have largely been attacking the same set of targets for decades: sodium channels, GABA receptors, calcium channels, and synaptic vesicle proteins.

Azetukalner does something none of them do. It targets Kv7 potassium channels, which act as a natural brake on neuronal excitability. When a neuron fires, it needs to reset before it can fire again. Kv7 channels are central to that reset process, helping clamp the neuron back to its resting state. In people with epilepsy, that brake is effectively too weak, allowing neurons to fire in rapid, synchronized bursts that propagate across brain circuits as a seizure. Azetukalner makes the brake stronger, reducing the probability that hyperexcitable neurons can sustain the kind of runaway firing that starts a seizure in the first place. No approved drug works this way.

Which brings us back to that March data readout. In Xenon's Phase 3 study, the 25 mg dose of azetukalner reduced monthly seizure frequency by 53% compared to just 10% for placebo. That placebo-adjusted gap of roughly 43 percentage points surpassed Xcopri, widely considered the most effective anti-seizure medication on the market, which had posted a 31 to 34% delta in its own trials. What made the number even more striking is that Phase 3 studies in this field almost never outperform Phase 2. Xenon's did, by eight percentage points.

The long-term data add another dimension. In an ongoing open-label extension study, patients who have been on azetukalner for 48 months are achieving greater than 90% median reduction in monthly seizures. Nearly 40% have gone twelve or more consecutive months without a single seizure, which is the clinical community's definition of seizure freedom. These are patients who, not long ago, were having a seizure nearly every other day.

Xenon plans to file a New Drug Application with the FDA in the third quarter of 2026, targeting approval for focal onset seizures. Peak annual sales estimates for that indication alone run around $1 billion. But the more interesting question is what happens beyond epilepsy. Azetukalner is currently in two Phase 3 studies for major depressive disorder and bipolar depression, with readouts expected in the first half of 2027. Kv7 channels are expressed in limbic brain regions involved in mood regulation, and an exploratory analysis in the epilepsy trial showed signals of antidepressant effect in patients not already on antidepressants. Depression and bipolar disorder are markets that dwarf epilepsy in size. If those studies succeed, the commercial ceiling looks entirely different.

What makes this interesting from an investor's perspective is that XENE is largely being valued on the epilepsy program alone, meaning those two depression readouts are essentially a free option embedded in the current price.

There are real risks however. Commercial execution in specialty neurology is hard, and newer ASMs have historically faced slower-than-expected uptake as physicians tend to be conservative about switching patients who are partially controlled on existing regimens.

But Xenon has something rare in this industry: a drug that appears genuinely better than anything else in its class, a mechanism that opens doors into multiple large diseases, and clinical data that have now been replicated across two rigorous trials in one of the hardest-to-treat patient populations in neurology.

The real question now is whether azetukalner is just the best epilepsy drug in a generation, or the beginning of something much larger.

Here is what I am into:

What I’m looking forward to
The new F1 regulations seem to be very controversial among the fans, but when Lewis Hamilton is happy, I am happy. I look forward to watching him race and hopefully enjoy his time on the track this year.

What caught my eye
A San Francisco startup called Muse Bio is paying women $40 to donate their menstrual fluid to harvest the stem cells inside it. The science is apparently real, and their first product is a skin serum, which conveniently sidesteps FDA regulation entirely.

Thank you for joining me to learn about Xenon Pharmaceuticals. For any questions or comments, you can reach me at [email protected]

Yours truly,
Mark Gad